By providing deeper understanding of immune responses, clinicians can better understand an appropriate course of action for patients while also prioritising the use of precious hospital resources, the company said
Becton, Dickinson and Company has announced the availability of its BD Multitest 6-Color TBNK Reagent with BD trucount tubes with an expanded clinical application in India to help identify COVID-19 patients at an increased relative risk of intubation with mechanical ventilation (IMV) and mortality, in conjunction with clinical findings and the results of other laboratory testing. By providing deeper understanding of immune responses, clinicians can better understand an appropriate course of action for patients while also prioritising the use of precious hospital resources, the company said in a statement.
Speaking on the importance of gauging the patient’s immunity profile, Pavan Mocherla, Managing Director, BD India/South Asia, said, “As India continues to battle with this unprecedented healthcare crisis in the wake of the second wave of COVID-19, application of this immune assessment-based IVD assay amongst COVID-19 patients could potentially ease out the already-choked healthcare infrastructure in the country by prioritising hospital admission and ICU beds to those who are at higher relative risk for requiring ventilator support and increased risk of mortality.”
“BD has a long working experience with CD4 monitoring for HIV patients through the National AIDS Control Organisation (NACO), Ministry of Health and Family Welfare (MOH&FW) in the country. We have been supporting researchers and clinicians to understand immune functions in cancer, primary immune-deficiency and COVID-19 vaccine research as well. We hope that availability of this assay kit in India for expanded COVID-19 clinical application helps in optimal utilisation of hospital resources,” added Pavan Mocherla.
The kit, which is approved for use in the European Union (EU), has been reviewed and approved by the Drugs Controller General of India (DCGI) to monitor the lymphocyte subsets for various applications. The test is conducted on a clinical flow cytometer, which is available with major hospitals and network laboratories across India. In the current scenario of COVID-19 crisis, this information can now equip the clinician with a deeper understanding of the patient’s immune status.
Considering the COVID-19 trend and the possibility of multiple waves in future, some research projections estimate a potential requirement of nearly 2,70,000 ICU beds which is over 2.8 times the estimated number of total available ICU beds in India. A major percentage of these may further require ventilators. This puts an insurmountable amount of pressure on the limited resources since the influx of patients into the hospitals is manifold. The situation across India in April 2021 was testimony for the same.
BD tools were utilised for research early in the pandemic and early publications showed that the BD Multitest 6-Color TBNK Reagent with trucount tubes was useful in assessing immune status for COVID-19 patients. Further, clinical studies have demonstrated clinically-validated cut-off levels and further refined the role BD Multitest 6-Color TBNK Reagent with trucount tubes, along with other testing in determining the COVID-19 patients’ risk of IMV and mortality at hospitalisation.
As shown in peer-reviewed clinical studies, some patients with COVID-19 may exhibit a decrease of specific lymphocyte T-cell subsets (CD4+ and/or CD8+ T-cells), and this decrease is associated with an increased risk of IMV and mortality. Knowing a patient’s accurate T-cell count, therefore, can be instrumental in informing the right course of action, and the BD Multitest 6-color TBNK Reagent with BD trucount tubes may aid in these types of determinations.